This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 18 print issues and online access
$259.00 per year
only $14.39 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ling JYM, Mansournia MA, Etminan M. Disease latency bias and the protective effect of metformin against age-related macular degeneration. Eye. 2024. https://doi.org/10.1038/s41433-024-02993-7.
NICE. NICE Guideline 28 Type 2 diabetes in adults: management. 2022. https://www.nice.org.uk/guidance/ng28/chapter/Recommendations#drug-treatment
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023. Diabetes Care. 2023;46:S140–S157. https://doi.org/10.2337/dc23-S009
Diabetes Association of the Republic of China (Taiwan). Executive summary of the DAROC clinical practice guidelines for diabetes care- 2018. J Formosan Med Assoc. 2023;19:577–86.
Romdhoniyyah DF, Harding SP, Cheyne CP, Beare NAV. Metformin, a potential role in age-related macular degeneration: a systematic review and meta-analysis. Ophthalmol Ther. 2021;10:245–60. https://doi.org/10.1007/s40123-021-00344-3
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Beare, N. Disease latency bias and the protective effect of metformin against age-related macular degeneration. Eye (2024). https://doi.org/10.1038/s41433-024-03112-2
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41433-024-03112-2